Application of PKMYT1 in inhibition of cell proliferation of chronic myeloid leukemia

By detecting and interfering with PKMYT1 expression and using the inhibitor RP-6306, the drug resistance problem to imatinib in CML patients was solved, significantly inhibiting CML cell proliferation and improving therapeutic effects, providing new therapeutic targets and Strategy.

CN118962137APending Publication Date: 2024-11-15重庆医科大学国际体外诊断研究院
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411008282.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing tyrosine kinase inhibitor imatinib has drug resistance, intolerance and recurrence after drug discontinuation in patients with chronic myeloid leukemia (CML), and new treatment strategies need to be found.

Method used

By detecting and verifying the expression of PKMYT1 in CML cells and its relationship with BCR-ABL, the shRNA lentiviral vector interferes with PKMYT1 expression, and the specific inhibitor RP-6306 is applied to inhibit the proliferation of CML cells and promote apoptosis.

Benefits of technology

It was confirmed for the first time that PKMYT1 is highly expressed in CML and inhibits cell proliferation. RP-6306 combined with imatinib treatment significantly improved the anti-tumor effect and provided new therapeutic targets and strategies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118962137A_ABST
    Figure CN118962137A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biomedical research, and particularly relates to application of PKMYT1 in inhibiting cell proliferation of chronic myeloid leukemia. The technical problem to be solved by the invention is to provide a new molecular target for treating CML leukemia. The expression of PKMYT1 in various solid tumors is found to be up-regulated, and the high expression of PKMYT1 is related to poor prognosis of a patient, but the high expression of PKMYT1 has not been reported in CML. The shRNA lentiviral vector or a high-selectivity inhibitor RP-6306 is utilized to target the PKMYT1, so that the growth capability of the CML cells can be effectively inhibited. The PKMYT1 is expected to become a novel molecular therapeutic target of the CML.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedical research, relates to a new target for treating chronic myeloid leukemia, and specifically relates to the application of PKMYT1 in inhibiting the proliferation of CML cells. Background Art

[0002] Chronic myeloid leukemia (CML) is a malignant fusion gene of the blood system caused by chromosomal translocation t(9;22)(q34;q11), which can control the synthesis of fusion protein BCR-ABL with tyrosine kinase activity. The use of tyrosine kinase inhibitor (TKI) imatinib (IM) can achieve good therapeutic effects in most patients, but some patients still have problems such as drug resistance, intolerance or relapse after drug withdrawal. Based on these problems, finding new treatment strategies and methods is quite critical for CML patients.

[0003] Membrane-associated tyrosine and threonine-specific CDC2 inhibitory kinase 1, or PKMYT1, is a member of the WEE kinase family as a cell cycle regulatory kinase. PKMYT1 mainly regulates cyclin-dependent kinase 1 (CDK1) by phosphorylating Tyr15 and Thr14 to inhibit its activity and prevent it from binding to cyclin B, thereby acting as a negative regulator of the cell cycle, preventing the cell cycle from entering the G2 / M phase, leading to delayed mitosis and prompting the completion of DNA replication. More and more studies have reported that abnormal expression of PKMYT1 is closely related to various types of cancer and plays an important role in cell proliferation. Interference with PKMYT1 or targeted inhibition can enable more cells to skip the G2 / M checkpoint to complete mitosis, thereby inhibiting cell proliferation and promoting cell apoptosis. Therefore, PKMYT1 is expected to become a new target for solving problems such as CML resistance and refractory. In addition, research on PKMYT1 in CML has not yet been reported. Summary of the invention

[0004] 1. The technical problem to be solved by the present invention is to provide a new molecular target for the treatment of CML to solve the problems raised in the background technology.

[0005] 2. To solve the above technical problems, an embodiment of the present invention provides an experimental verification of the application of PKMYT1 in inhibiting the proliferation of CML cells, characterized in that it includes the following steps:

[0006] (1) Detection of PKMYT1 expression in CML and its relationship with BCR-ABL: First, quantitative real time PCR (qRT-PCR) and Western blot were used to detect the gene and protein expression levels of PKMYT1 in CML cell lines. Second, Western blot was used to detect the relationship between PKMYT1 and BCR-ABL.

[0007] (2) Effect of shRNA lentiviral vector interference with PKMYT1 expression on CML cell proliferation: We first used shRNA lentiviral vectors to interfere with PKMYT1 expression in K562, KCL22 and K562 / G01 cell lines, and used qRT-PCR, Western blot and immunofluorescence (IF) to detect the expression level of PKMYT1. Then, we used the Cell Counting Kit-8 (CCK-8), clone formation assay and flow cytometry (FCM) to detect the proliferation ability of CML cells in vitro and observe changes in cell cycle and apoptosis.

[0008] (3) Effects of PKMYT1-specific inhibitor RP-6306 on CML cell proliferation in vitro and in vivo: In in vitro experiments, RP-6306 was used to treat various CML cell lines, and CCK-8, FCM and Western blot experiments were used to detect the effects of RP-6306 on CML cell proliferation. In in vivo experiments, RP-6306 combined with IM was used to continuously treat xenograft CML model mice, and the treatment effect was dynamically observed by in vivo imaging, and the weight of the mice was recorded.

[0009] 3. Compared with the prior art, the present invention has the following advantages

[0010] (1) This invention reports for the first time that PKMYT1 is highly expressed in CML and inhibits cell proliferation, playing a role in promoting cancer in CML, suggesting that PKMYT1 is expected to become a new molecular target for the treatment of CML.

[0011] (2) The present invention reports for the first time that RP-6306 inhibits cell proliferation, promotes cell apoptosis, and affects cell cycle distribution in CML, and verifies in vivo that it has a good anti-tumor effect when combined with IM. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] In order to more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the following briefly introduces the drawings required for use in the embodiments or the prior art description:

[0013] Figure 1PKMYT1 is highly expressed in CML cells and depends on BCR-ABL to function. (A) RT-qPCR to detect the expression of PKMYT1 in CML cell lines; (B) Western blot to detect the expression of PKMYT1 in CML cell lines; (C) The expression of PKMYT1 after K562, KCL22 and K562 / G01 were treated with different concentrations of IM. ***P<0.001, ****P<0.0001.

[0014] Figure 2 shRNA lentiviral vector interference with PKMYT1 inhibits CML cell proliferation. (A) RT-qPCR to detect the interference efficiency of PKMYT1; (B) Western blot to detect the interference efficiency of PKMYT1; (C) Immunofluorescence to detect the interference efficiency of PKMYT1. (D) Flow cytometry to detect the effect of interference with PKMYT1 on the cell cycle; (E) CCK-8 to detect the activity of CML cells after interference with PKMYT1; (F) Cloning assay to detect the colony size and number of CML cells after interference with PKMYT1. ***P<0.001, ****P<0.0001.

[0015] Figure 3 RP-6306 inhibits CML cell proliferation in vitro and has a stronger anti-tumor effect in combination with IM in vivo. (A) Western blot was used to detect the expression of PKMYT1 protein in K562, KCL22, and K562 / G01 cells before and after RP-6306 treatment; (B) CCK-8 was used to detect the activity of K562, KCL22, and K562 / G01 cells before and after RP-6306 treatment; (C) Flow cytometry was used to detect the cell cycle distribution of K562, KCL22, and K562 / G01 cells after treatment with different concentration gradients of RP-6306. (D) Flow cytometry was used to detect the apoptosis of K562, KCL22, and K562 / G01 cells after treatment with different concentration gradients of RP-6306; (E) HE staining was used to observe the inflammation of the liver, kidney, lung, and small intestine of mice after treatment with 5 mg / kg and 10 mg / kg RP-6306. (F) Dynamic evaluation of tumor distribution in mice by in vivo imaging; (G) Changes in mouse body weight; (H) Tumor infiltration in the liver, spleen, and bone marrow of mice. *P<0.05, **P<0.01, ****P<0.0001. DETAILED DESCRIPTION

[0016] The present invention will be further described below in conjunction with specific embodiments, and the advantages and features of the present invention will become clearer as the description proceeds. However, these embodiments are exemplary only and do not constitute any limitation to the scope of the present invention. It should be understood by those skilled in the art that the details and forms of the technical solution of the present invention may be modified or replaced without departing from the spirit and scope of the present invention, but these modifications and replacements all fall within the scope of protection of the present invention.

[0017] 1. Experimental Methods

[0018] (1) Cultivation method of leukemia cells in the present invention: K562, KCL22 and K562 / G01 cell lines were cultured in RPMI 1640 medium containing 10% fetal bovine serum in an incubator at 37°C and 5% CO2. The cells were passaged every 1-2 days on average, and the cells in the logarithmic growth phase were collected for subsequent related experiments.

[0019] (2) Method for detecting PKMYT1 gene expression level by qRT-PCR in the present invention

[0020] (a) RNA extraction: 1×10 6 cells, washed three times with pre-cooled PBS at 1000rpm×5min; discard the supernatant, add 1mL RNA extraction reagent TRIzol, shake and mix thoroughly, let it stand on ice for 10min to lyse and layer; then, add 200μL of chloroform, mix up and down until the solution turns pink, let it stand on ice for 10min, and centrifuge at 4℃ at 13000rpm×10min; aspirate 400μL of supernatant solution into a pre-cooled new enzyme-free EP tube, add isopropanol with an equal volume of chloroform, mix up and down, let it stand on ice for 10min, and centrifuge at 4℃ at 13000rpm×5min; discard the supernatant, add 1ml of freshly prepared 75% ethanol solution (DEPC water: anhydrous ethanol = 1:3), wash the precipitate, and wash it three times by centrifugation at 4℃ at 7500rpm×5min; discard the supernatant, and after the ethanol evaporates completely, add an appropriate amount of RNase according to the amount of precipitate Free double distilled water was used to dissolve the RNA; finally, the RNA concentration and purity were determined and stored at -80°C.

[0021] (b) Reverse transcription

[0022] ① Removal of genomic DNA reaction (reaction procedure: 42°C × 2 min, 4°C cooling)

[0023]

[0024] ② Reverse transcription reaction (reaction procedure: 37℃×15min, 85℃×5s, 4℃ cooling)

[0025]

[0026] (c) qRT-PCR

[0027]

[0028] Reaction procedure: Two-step PCR amplification standard procedure: Stage 1 Pre-denaturation: 95℃30s (Reps: 1) Stage 2 PCR reaction: 95℃5s--60℃30s (Reps: 40) Stage 3 Dissociation After the reaction is completed, observe whether the amplification and melting curves show a "single peak" to ensure the uniqueness of the primers for RNA amplification.

[0029] Result analysis (RNA expression calculation): The reaction used GAPDH gene as the internal reference, and the 2-△△Ct method was used to calculate the expression of the target gene relative to the internal reference gene. Calculation formula: △△Ct = (average Ct value of target gene - average Ct value of internal reference gene) experimental group - (average Ct value of target gene - average Ct value of internal reference gene) control group. The primer sequences of each target gene are shown in the following table:

[0030]

[0031] (3) Method for detecting protein expression level by Western blot in the embodiment of the present invention:

[0032] (a) Sample preparation

[0033] First, calculate the volume of the protein to be tested (30 μg / protein concentration), add 4 μL of protein loading buffer (reducing 5×), and add deionized water to 20 μL. Then, centrifuge for 10 seconds, vortex for 15 seconds, place in a 100°C metal bath for denaturation for 15 minutes, and transfer to 4°C for use after reaching room temperature.

[0034] (b) Preparation of separation gel and stacking gel

[0035] Equilibrate the PAGE gel rapid preparation kit at room temperature for 30 minutes. Prepare the separation gel according to the instructions of the kit, and prepare each gel according to the ratio of 8mL lower gel solution + 8mL lower gel buffer + 80μL improved coagulant. Add 7.2mL of the prepared separation gel to the gel glass plate, and flatten the separation gel with 2mL of anhydrous ethanol, and solidify at room temperature; after the separation gel can be seen to be clearly separated from the anhydrous ethanol, pour off the upper anhydrous ethanol; prepare the concentrated gel, and prepare each gel according to the ratio of 1.5mL lower gel solution + 1.5mL lower gel buffer + 30μL improved coagulant. Fill the prepared concentrated gel in the gel glass plate, and slowly insert the sample comb, and solidify at room temperature;

[0036] (c) Electrophoresis

[0037] After the concentrated gel solidifies, fix the gel-making glass plate in the electrophoresis core. Soak the electrophoresis core in Tris-glycine SDS-PAGE common electrophoresis buffer for 5 minutes, pull out the loading comb; spot samples in the order of large marker (5μL)-protein sample (20μL)-small marker (2μL); adjust the constant voltage to 80V for electrophoresis, and switch the power supply voltage to 120V after bromophenol blue enters the separation gel and continue electrophoresis until bromophenol blue runs to the green gel strip under the electrophoresis core and stops electrophoresis;

[0038] (d) Transfer

[0039] Prepare transfer buffer: dilute the transfer buffer (powder) to 1600mL, then add 400mL of methanol solution to dilute to 2000mL, and precool to 4°C in advance; first immerse the PVDF membrane in methanol for 30s to activate, then soak it in transfer buffer for 10min, and then put it into the electrotransfer buffer together with filter paper and gel; put the sponge, filter paper, gel, PVDF membrane, filter paper, and sponge in order according to the sandwich method, with the PVDF membrane on the anode side and the gel on the cathode side (black gel and white film), and insert them into the transfer tank in the direction of the transparent plate to the red side and the black plate to the black side; use a constant voltage of 75V to transfer for 1.5h.

[0040] (e) Closed

[0041] Prepare 5% skim milk, place on a horizontal shaker, and mix for 5 minutes; immerse the PVDF membrane in TBST and wash on a horizontal shaker for 5 minutes; place the PVDF membrane in 5% skim milk and block on a horizontal shaker at room temperature for 1 hour; after blocking, immerse the PVDF membrane in TBST and wash off the residual milk on the membrane on a horizontal shaker;

[0042] (f) Primary antibody incubation

[0043] Immerse the PVDF membrane in the primary antibody incubation box containing the target antibody and incubate it on a horizontal shaker at 4°C overnight (12-14 h).

[0044] (g) Secondary antibody incubation

[0045] The PVDF membrane was taken out from the primary antibody incubation box, placed in TBST, and washed on a horizontal shaker for 3 times, 10 min each time; the secondary antibody diluted in TBST was added to the washed PVDF membrane, and incubated on a horizontal shaker at room temperature for 1.5 h.

[0046] (h) Chemiluminescence

[0047] The PVDF membrane was removed from the antibody incubation box, placed in TBST, and washed three times on a horizontal shaker, each time for 10 min. According to the instructions of the ultra-sensitive ECL chemiluminescence kit, equal volumes of solution A and solution B were mixed, and then evenly sprinkled on the surface of the PVDF membrane, and placed in a gel imager for imaging.

[0048] (i) PVDF membrane regeneration

[0049] Place the chemiluminescent strips in TBST and wash on a horizontal shaker for 10 minutes; pour out the TBST and add 15 mL of antibody elution buffer (enhanced) for elution, and wash on a horizontal shaker for 20 minutes; pour out the antibody elution buffer, add TBST, and wash on a horizontal shaker for 10 minutes; the steps of (e) blocking, (f) primary antibody incubation, (g) secondary antibody incubation, (h) chemiluminescence, and (i) PVDF membrane regeneration can be repeated in sequence.

[0050] (4) Method for interfering with the expression of PKMYT1 by lentivirus in the embodiments of the present invention

[0051] Lentivirus packaging, sequencing and titer determination: The shRNA lentiviral vector targeting the PKMYT1 gene (shPKMYT1) was synthesized, packaged, sequenced and identified by Shanghai GeneChemical Technology Co., Ltd., and the virus titer was determined. The shRNA sequence is:

[0052] shPKMYT1#1:5'-GCTGCGTTCTGTCCTTGTCAT-3'

[0053] shPKMYT1#2:5'-CCTTGATGTCAAGCCTGCCAA-3'

[0054] shPKMYT1#3:5'-CTATGCGGTAAAGCGTTCCAT-3'

[0055] Lentivirus infected cells and screened stable cell lines: Calculate virus volume = (MOI × number of cells) / virus titer (the transfection culture plate used is a 6-well plate, and the number of cells used in each well is 2 × 10 5 ), inoculate the cells in a six-well plate, add 80 μL HitransGA infection enhancement solution (25×) and the calculated volume of lentivirus, and supplement the total volume of the culture medium to 2 mL. Shake the cells thoroughly and culture them in a 37°C cell culture incubator. After 15 hours of cell infection, centrifuge at 1500 rpm for 2 minutes to terminate; observe the cell infection efficiency under a fluorescence microscope 48 hours after cell termination. When the cell infection efficiency is ≥70%, add 8 μL (final concentration 4 μg / mL) of puromycin to each well for screening, repeat three times, and replace the six-well plate after each screening until the cell transfection efficiency is ≥95%, and then conduct subsequent experiments.

[0056] (5) Immunofluorescence (IF) method in the embodiments of the present invention

[0057] First, collect the cells, centrifuge at 1000rpm for 5min, wash 3 times with PBS and discard the supernatant; resuspend the cells with an appropriate amount of PBS, take a small amount of cells and evenly apply them on a glass slide to dry naturally; then, fix the cells with 4% paraformaldehyde, leave them at room temperature for 15min, wash with PBS for 5min each time, repeat 3 times; then add 0.5% Triton X-100, permeabilize in a 37℃ water bath for half an hour, wash 3 times with PBS for 5min each time; absorb the excess PBS, add goat serum to cover the glass slide, and block at 4℃ for 1h; add primary antibody diluted with goat serum (1:100), incubate at 4℃ overnight, wash 3 times with PBS for 5min each time; ... The slides were incubated with Cy-3 labeled secondary antibody (1:1000) diluted with X-100 at 37°C for 1 hour, and washed with PBS three times for 5 minutes each time. The slides were added with diluted DAPI staining solution, incubated in a 37°C water bath for half an hour, and washed with PBS three times for 5 minutes each time. After natural air drying, appropriate amount of glycerol was absorbed for sealing. The slides were photographed and observed under a laser confocal microscope.

[0058] (6) Method of CCK-8 experiment in the present invention

[0059] The cells from each group were collected and 5×10 3 The cells were inoculated in a 96-well plate, with 5 replicate wells in each group and a blank control, and the cells were cultured in an incubator. 10 μL CCK-8 reagent was added to each well at 0, 24, 48 and 72 h of culture, and the culture was continued for 3 h after mixing. The absorbance (OD) value was detected at a wavelength of 450 nm, and the cell proliferation curve was drawn with OD450 value as the ordinate and culture time as the abscissa.

[0060] (7) Method for detecting cell proliferation by clone formation assay in the embodiment of the present invention

[0061] The treated cells were collected and counted, 100 cells were seeded per well in a 96-well plate and cultured for 7 days, and then the colonies were counted and photographed using an inverted microscope.

[0062] (8) Method for detecting cell cycle and apoptosis by FCM experiment in the embodiment of the present invention

[0063] Cell cycle: Collect at least 1 × 10 6Add 100 μL of cells to a 5 mL flow cytometer tube and collect the cells by centrifugation at 2000 rpm for 5 min. Wash the cells once with pre-cooled PBS and resuspend the cells in 100 μL PBS. Add 1 ml of 75% pre-cooled ethanol dropwise to the cell suspension, fix for 2.5 h, centrifuge at 2000 rpm for 5 min, remove the ethanol, and wash twice with pre-cooled PBS. Add 50 μL of 100 μg / mL ribonuclease A and incubate for 5 min, then add 425 μL of PBS and 10 μL of Propidium Iodide Solution and stain for 20 min. Centrifuge at 2000 rpm for 5 min to remove excess PI dye, and complete the detection within 30 min.

[0064] Apoptotic cells: Collect at least 1 × 10 6 cells, washed twice with pre-cooled PBS, added 100 μL Annexin V Binding Buffer; then added 8 μL APC Annexin V and 5 μL Propidium Iodide Solution, gently vortexed to mix, incubated at 4°C in the dark for 15 min; centrifuged at 2000 rpm for 5 min, added 500 μL Annexin V Binding Buffer to resuspend, and tested on the machine.

[0065] (9) HE staining method in the present invention

[0066] Place the paraffin sections in environmentally friendly dewaxing solution I for 20 minutes, environmentally friendly dewaxing solution II for 20 minutes, anhydrous ethanol for 15 minutes, anhydrous ethanol II for 5 minutes, and 75% alcohol for 5 minutes, and finally wash with tap water. Place the sections in high-definition constant staining pretreatment solution for 1 minute. Place the sections in hematoxylin hematoxylin staining solution for 3-5 minutes, wash with tap water, differentiate with differentiation solution, wash with tap water, and then return to blue with blue solution, and finally rinse with running water. Subsequently, place the sections in 95% alcohol for 1 minute and then place them in eosin staining solution for 15 seconds. Then, place the sections in anhydrous ethanol I for 2 minutes, anhydrous ethanol II for 2 minutes, anhydrous ethanol III for 2 minutes, n-butanol I for 2 minutes, n-butanol II for 2 minutes, xylene I for 2 minutes, and xylene II for 2 minutes to make them transparent, and seal the sections with neutral gum. Finally, perform microscopic examination and collect images.

[0067] (10) Construction of NSG mouse blood tumor model in the present invention

[0068] According to the method of lentiviral infection of cells, Luciferase-NC lentivirus was transferred into KCL22, and the cells were screened into stable cell lines using puromycin; KCL22 cells carrying Luciferase were collected by centrifugation at 3000 rpm for 5 min, and the cells were washed twice with PBS. According to the counting results, the cell concentration was adjusted to 2.5×10 7 / mL, and place on ice for later use; use a BD insulin syringe to draw 8 units (0.2mL) of cell suspension and empty the bubbles in the syringe; take the NSG mouse out of the cage, fix it in a fixed frame, use an insulin syringe to horizontally insert the needle into the tail vein, and slowly push the cell suspension (5×10 6 / piece, 0.2 ml each).

[0069] 2. Experimental results

[0070] (1) PKMYT1 is highly expressed in CML cells and depends on BCR-ABL to function

[0071] To detect the expression of PKMYT1 in CML, we used qRT-PCR and Western The expression of PKMYT1 in K562 (Imatinib sensitive cell line), KCL22 (Imatinib moderately resistant cell line), K562 / G01 (Imatinib resistant cell line) and other leukemia cell lines SUP-B15 (acute lymphoblastic leukemia), THP-1 (acute monocytic leukemia), U937 (histiocytic lymphoma cells) and HS5 (bone marrow stromal cells) was detected by blot. As shown in the figure (1A-B), compared with HS5 cells, the PKMYT1 gene and protein levels were relatively highly expressed in CML cells. After treating CML cells with different concentrations of IM for 48 hours, the expression levels of PKMYT1 and p-BCR / ABL were detected by Western blot. As shown in the figure (1C), the expression levels of PKMYT1 and p-BCR / ABL were both reduced and concentration-dependent. The above results indicate that PKMYT1 is significantly highly expressed in CML cells and depends on BCR-ABL to exert its effects.

[0072] (2) shRNA lentiviral vector interferes with PKMYT1 to inhibit CML cell proliferation

[0073] In order to observe the effect of lentiviral interference with PKMYT1 on the proliferation of CML cells, we first detected the expression of PKMYT1 in CML cells after interference with PKMYT1 by qRT-PCR, Western blot and IF. As shown in the figure (2A-B), compared with the shControl group, the shPKMYT1 group can effectively reduce the mRNA and protein levels of PKMYT1; as shown in the figure (2C), the immunofluorescence results showed that the fluorescence intensity of the shPKMYT1 group was weakened. Next, we used FCM experiments to detect the changes in the CML cell cycle after interference with PKMYT1. As shown in the figure (2D), knocking down PKMYT1 reduced the G2 / M phase arrest. Finally, the proliferation of CML cells after interference with PKMYT1 was detected by CCK-8 and clone formation experiments. As shown in the figure (2E-F), interference with PKMYT1 inhibited the proliferation of CML cells. The above results suggest that lentiviral interference with PKMYT1 will inhibit the proliferation of CML cells and reduce the G2 / M phase arrest.

[0074] (3) RP-6306 inhibits CML cell proliferation in vitro and has a stronger anti-tumor effect when combined with IM in vivo

[0075] In order to observe the effect of PKMYT1 specific inhibitor RP-6306 on CML cells in vivo and in vitro, first, we treated CML cells with 0.5μM RP-6306 for 48h, and then used Western blot to detect the expression of PKMYT1 protein in each cell before and after RP-6306 treatment. As shown in the figure (3A), RP-6306 treatment reduced the protein expression level of PKMYT1 in CML cells, indicating that RP-6306 effectively inhibited the expression of PKMYT1 in cells. Then, CCK-8 experiment was used to detect the changes in the growth ability of CML cells after 48h treatment of CML cell lines with different concentrations of RP-6303: 0μM, 0.001μM, 0.01μM, 0.1μM, 1μM and 10μM. As shown in the figure (3B), the growth ability of CML cells was significantly reduced. The above results suggest that RP-6306 can inhibit the proliferation ability of CML cells in vitro. Subsequently, in order to observe the effect of RP-6306 on CML cell cycle and apoptosis, FCM experiments were performed to detect the changes in CML cell cycle after 48h treatment of CML cell lines with different concentrations of RP-6306: 0μM, 0.2μM, 0.5μM and 1μM. As shown in the figure (3C), after RP-6306 treatment, the G2 / M phase arrest of CML cells was reduced. In addition, the changes in CML cell apoptosis. As shown in the figure (3D), after RP-6306 treatment, CML cell apoptosis increased.

[0076] Finally, the effect of RP-6306 on proliferation in vivo was observed. First, we set up 5mg / kg and 10mg / kg concentrations of RP-6306 for two consecutive weeks in NSG mice to detect the safety of RP-6306. As shown in the figure (3E), the HE staining results showed that there was no obvious inflammatory infiltration in the liver, kidney, lung and small intestine of the mice, indicating that RP-6306 has a certain safety. Then we constructed a CML mouse blood tumor model and divided the drugs into groups. The treatment effect was dynamically evaluated by in vivo imaging. As shown in the figure (3F-H), the RP-6306 combined with IM treatment group had the least tumor cell distribution, the lightest weight loss, and reduced CML cell infiltration in the liver, spleen and bone marrow of the mice. The above results show that RP-6306 has a better anti-tumor effect than the IM group.

Claims

1. An experimental validation of the application of PKMYT1 in inhibiting the proliferation of chronic myeloid leukemia cells.

2. The use according to claim 1, characterized in that PKMYT1 is highly expressed in CML and depends on BCR-ABL to function.

3. The use according to claim 1, characterized in that Interference in PKMYT1 expression inhibits CML cell proliferation.

4. The use according to claim 3, characterized in that The shRNA lentiviral vector was used to interfere with the expression of PKMYT1 in CML cells, inhibit the proliferation of CML cells, and affect the cell cycle distribution.

5. The use according to claim 3, characterized in that The method of interfering with the expression of PKMYT1 in CML cells using the PKMYT1 specific inhibitor RP-6306 is as follows: (1) Using RP-6306 to interfere with PKMYT1 expression in vitro; (2) RP-6306 combined with imatinib was used in vivo to interfere with the expression of PKMYT1.

6. The use according to claim 5, characterized in that The RP-6306 has the following effects in CML: (1) RP-6306 was used in vitro to inhibit CML cell proliferation, promote cell apoptosis, and affect cell cycle distribution; (2) The combined use of RP-6306 and imatinib in vivo has a better anti-tumor effect.